Skip to content
2000
Volume 5, Issue 4
  • ISSN: 1574-888X
  • E-ISSN: 2212-3946

Abstract

Systemic available circulating cells play a role in cardiac maintenance and ameliorate cardiac recovery and repair after myocardial infarction. However, only a small number of cells will be incorporated during cardiac damage. Cell mobilization, homing to the ischemic myocardium and engraftment are complex processes depending on many adhesion molecules, proteases, chemokines and their receptors. Physiologic and pathophysiologic circumstances, cytokines, chemokines and certain drugs are able to influence these processes. For cardiovascular regeneration, understanding how mobilization and homing of blood derived cells is regulated and can be modulated as well as identification of cell populations able to regenerate the heart or reduce damage after myocardial infarction is essential for the development of successful cell based therapies.

Loading

Article metrics loading...

/content/journals/cscr/10.2174/157488810793351712
2010-12-01
2025-09-18
Loading full text...

Full text loading...

/content/journals/cscr/10.2174/157488810793351712
Loading

  • Article Type:
    Research Article
Keyword(s): activated by monocyte chemoattractant protein 1; Activation by Chemoattractants; adenomas; Adenoviral mediated plasma; adenovirus; adipose tissue; angina pectoris; anti-hypertensive drugs; antigen-1; atherosclerotic plaques; ATP-binding; Blood cells; blood EPC counts; bone marrow derived cells; cardiac chimerism; cardiac function; cardiac regeneration; Cardiac Regeneration; Cardiac wound healing; cardiomyocyte shrinkage; cartilage; Cell arrest; cell death; cell infusion; CELL MOBILIZATION; Cell Trafficking; cellular therapy; chamber dilatation; chemotactic response; chemotaxis of progenitor cells; cleavage of stromal cell membrane; co-internalize; conventional therapy; coronary artery obstruction; culture plastic; cysteine protease; cytokines; damage reduction; dilated cardiomyopathy; dysfunctional part; Endothelial Progenitor Cells; EPC-integrin binding; erythroid; growth factors; heart failure; hematologists; hematooncologic diseases; Hematopoietic Stem Cells; high tensile strength; homed cells; homing; hyperlipidemia; hypoxia inducible factor-1α; ibesartan; in-stent reocclusion; inflammatory phase; influx; infusion; insulin-like growth factor; ischemia-reperfusion model; ischemic; Ischemic heart disease; left ventricular ejection fraction; ligand; lymphocytes; macrophages; maturation; mature lymphocytes; Meta-analyses; metalloproteinase; mobilization; monocytic origin; mononuclear cells; murine; myocardial infarction; N-terminus cleavage; necrosis; neovascularisation capacity; neutrophil elastase; nitric oxide synthase; parabiosis experiments; paracrine mechanism; peripheral blood; physiologic conditions; physiological conditions cardiomyocytes; placental growth factor; plasma cells; plasma soluble; Primary percutaneous coronary intervention; pro-angiogenic factors; progenitor cell; quail embryo; remodeling phase acellular; restenosis; sex-mismatched transplantations; SP cells; SUBPOPULATIONS FOR CARDIAC REGENERATION; tendon; tensile strength; tumor vascular endothelium; vascularization; ventricular ejection; X-Y mismatch heart
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test